30 Results for "

B7H4

" in MedChemExpress (MCE) Product Catalog:
Products (30)

30 Results for "B7H4" in MCE Product Catalog:

  • Recombinant Proteins Recommended:
2
2 Cited Publications
Cat. No.: HY-P74394
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: V-set domain containing T-cell activation inhibitor 1; VTCN1; Protein B7S1; B7-H4
Species:  
Source:  
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99242
CAS No.: 2254029-91-7

Target:  

CD276/B7-H3

Research Areas:  

Cancer

Alsevalimab is a humanized, afucosylated IgG1 monoclonal antibody against B7-H4. Alsevalimab blocks the binding of the B7-H4 protein to the receptors on the surface of T cells, reversing the immunosuppressive state in the tumor microenvironment, thereby activating the killing effect of T cells on cancer cells. Alsevalimab can be used in combination with Pembrolizumab (HY-P9902), and shows good safety profiles .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P74395
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: V-set domain containing T-cell activation inhibitor 1; VTCN1; Protein B7S1; B7-H4
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-149878
CAS No.: 3037514-38-5
Purity:  98.81%
Research Areas:  

Cancer

BD-9136 is a selective BRD4 PROTAC degrader with a DC50 of 1.2 nM, and exhibits a selectivity of ≥1000-fold over BRD2 and BRD3. BD-9136 preferentially forms a ternary complex with the BD1 domain of BRD4, and downregulates the expression of B7-H4 by disrupting the PR-P300-BRD4 axis. BD-9136 depletes BRD4 protein in tumor tissues, inhibits tumor growth, reduces B7-H4 protein expression, increases CD8+ T cell infiltration, and enhances tumor sensitivity to anti-PD-L1. Degradation of BRD4 by BD-9136 rescues the erythroid differentiation block induced by LSD1 inhibition, and transient administration restores erythroid output while retaining HbF induction. BD-9136 causes no adverse effects in mice at effective doses. BD-9136 can be used in studies related to acute myeloid leukemia, acute lymphoblastic leukemia and breast cancer .
loading...
    loading...
Cat. No.: HY-171689
CAS No.: 2760250-80-2
Synonyms: AZD 8205; P-Sam
Research Areas:  

Cancer

Puxitatug samrotecan (AZD 8205) is a B7-H4-directed antibody-drug conjugate (ADC) bearing a Topoisomerase I inhibitor (TOP1i) payload. Puxitatug samrotecan improves HR +/HER2 - breast cancer .
loading...
    loading...
Cat. No.: HY-P991703
CAS No.: 3042847-92-4
Synonyms: GSK5733584 antibody; HS-20089 antibody; hu2F7

Target:  

CD276/B7-H3

Research Areas:  

Cancer

Mocertatug (GSK5733584 antibody) is a humanized IgG1κ antibody targeting B7-H4/VTCN1. Mocertatug can be used to construct ADCs, such as Mocertatug Rezetecan (HY-185280) .
loading...
    loading...
Cat. No.: HY-P990059
CAS No.: 2760250-47-1
Synonyms: INT-016; AZD8205 Antibody

Research Areas:  

Cancer

Puxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer .
loading...
    loading...
Cat. No.: HY-P990953
CAS No.: 2640279-10-1
Synonyms: Gen1047

Target:  

CD3

Research Areas:  

Cancer

Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of B7H4-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of B7H4-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer) .
loading...
    loading...
Cat. No.: HY-177542
CAS No.: 2855974-40-0
Synonyms: Emi-Le; XMT-1660
Research Areas:  

Cancer

Emiltatug ledadotin (Emi-Le; XMT-1660) is a B7-H4-targeted antibody-drug conjugate (ADC). Emiltatug ledadotin consists of the tumor-specific anti-B7-H4 monoclonal antibody Emiltatug (HY-P990918) and the linker-payload system Ledadotin (HY-177541), with site-specific conjugation achieved via GlycoConnect click chemistry. Emiltatug ledadotin inhibits the growth of B7-H4-positive cancer cells. Emiltatug ledadotin can be used to study advanced solid tumors with B7-H4 overexpression, particularly breast cancer, ovarian cancer, and endometrial cancer .
loading...
    loading...
Cat. No.: HY-P991223

Research Areas:  

Cancer

NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
loading...
    loading...
Cat. No.: HY-148696A
CAS No.: 2414254-49-0
Research Areas:  

Cancer

Gly-Cyclopropane-Exatecan involves in the synthesis of anti-B7-H4 ADC, containing Exatecan (HY-13631), a DNA Topoisomerase I inhibitor. Gly-Cyclopropane-Exatecan participated in the formation of the ADC hu2F7-Exatecan (compound 34), which showed antitumor activity in vivo and in vitro .
loading...
    loading...
Cat. No.: HY-RS15721
Research Areas:  

Others

VTCN1 Human Pre-designed siRNA Set A contains three designed siRNAs for VTCN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-P990341

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology

Anti-B7-H4/VTCN1 Antibody is a CHO-expressed human antibody that targets B7-H4/VTCN1. The Anti-B7-H4/VTCN1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H4/VTCN1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
loading...
    loading...
Cat. No.: HY-P78073
Purity:  ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: B7H4; B7-H4; B7S1; B7h.5; B7x; FLJ22418; VTCN1; PRO1291
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P81427
Synonyms: B7X; B7H4; B7S1; B7-H4; B7h.5; VCTN1; PRO1291

Host:  

Rabbit

Application:  

IHC-P

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-P81427A
Synonyms: B7X; B7H4; B7S1; B7-H4; B7h.5; VCTN1; PRO1291

Host:  

Rabbit

Application:  

IHC-P

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-185761
Research Areas:  

Others

ADC Control Human IgG1-rezetecan is an isotype-matched control antibody-drug conjugate (ADC) for Mocertatug rezetecan (HY-185280). Mocertatug rezetecan is an ADC targeting B7-H4 .
loading...
    loading...
Cat. No.: HY-P704416
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: V-set domain containing T-cell activation inhibitor 1; VTCN1; Protein B7S1; B7-H4
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-P75485
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: V-set domain containing T-cell activation inhibitor 1; VTCN1; Protein B7S1; B7-H4
Species:  
Rat
Source:  
loading...
    loading...
Cat. No.: HY-P74395Y
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: V-set domain containing T-cell activation inhibitor 1; VTCN1; Protein B7S1; B7-H4
Species:  
Source:  
loading...
    loading...